Histologically or cytologically proven advanced (stage IIIB/IV) NSCLC subjects who are immunotherapy nave.
Histologically-confirmed stage IIIb or IV NSCLC by the enrolling institution\r\n* Patients who are highly suspected to have stage IIIb or IV NSCLC and who are planned for a standard-of-care diagnostic biopsy/resection may also be enrolled; patients who are confirmed to have stage IIIb or IV NSCLC will be eligible to continue with screening procedures; those who are found after surgery/biopsy to not have stage IIIb or IV NSCLC will not be eligible continue with screening procedures and may not receive study therapy
Phase  Cohorts A & B: Subjects must have a histologically or cytologically confirmed diagnosis of locally advanced (AJCC stage IIIB) not amenable to curative therapy or metastatic (AJCC stage IV) NSCLC that carries a RET rearrangement, as determined by FISH, RT-PCR, or NGS via a CLIA-certified LDT
Histologically or cytologically confirmed Stage IIIb or IV breast cancer with cutaneous metastases.
Histologically or cytologically confirmed advanced (stage IIIB or IV) NSCLC
Pathologically documented Stage IB, II, IIIA, or selected IIIB, including TN or T (by size criteria, not by mediastinal invasion) NSCLC
NSCLC that is clinically T by virtue of mediastinal organ invasion or Stage IIIB by virtue of N disease
Stage IIIB or IV NSCLC or relapsed locally advanced or metastatic NSCLC
Unresectable stage II, IIIA, or IIIB disease
Histologically diagnosed or cytologically proven advanced or metastatic NSCLC patients, either Stage IIIB/Stage IV disease (according to Version  of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or recurrent disease following radiation therapy or surgical resection;
Subjects must have histologically or cytologically-documented stage IIIB or stage IV, recurrent, or metastatic non-small cell lung cancer (NSCLC)
Biopsy-confirmed CD+ mycosis fungoides or Szary syndrome, stage IB to IIIB
Stage IIIB or IV NSCLC (any histology) at the time of study entry
Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC.
Patients with a diagnosis of cytologically or histologically documented adenocarcinoma of the lung with either metastatic disease (stage IV), Stage IIIB or Stage IIIC disease not amenable to surgery with curative intent
Individuals with stage IIIB or IV, unresectable non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for stage IIIB or IV disease, and who are not candidates for curative surgery or radiation therapy
A history of AJCC stage IIIB/C or stage IV melanoma but no current clinical evidence of metastatic disease
Stage IIIb
Patients with histologically or cytologically documented squamous or non-squamous NSCLC with stage IIIB or stage IV disease, who received no prior systemic treatment for recurrent or metastatic NSCLC
Patients with stage IIIB (not eligible for definitive chemo-radiotherapy), stage IV, or recurrent non-small cell lung cancer (NSCLC); patients with stage IV NSCLC should have previously received platinum based doublet chemotherapy; patients with a new diagnosis of stage IV NSCLC are eligible if they have an initial requirement for palliative (radiation therapy) XRT for symptomatic lesion (example: painful bone lesion or obstructive airway)
Pathologically or cytologically documented stage IIIB/IV non-small cell lung cancer, or unresectable recurrent disease following locoregional treatment
Completely surgically resected stage IIIb/c/d or stage IV melanoma within  weeks of participation in study.
Age ?  years with histologically confirmed diagnosis of melanoma and stage IIIB to IVMc for whom surgery is not recommended.
Subject has definitive histologically or cytologically confirmed Stage IIIB or IV NSCLC.
No prior systemic treatment for unresectable stage IIIB or IV NSCLC
Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC
Histologically confirmed diagnosis of stage IIIB, IIIC or IVMa melanoma eligible for complete surgical resection.
Participant must have metastatic or advanced NSCLC (Stage IIIB or IV) that is not amenable to surgical resection or radiation or chemoradiation with curative intent at time of study screening.
Pathologically (histologically or cytologically) proven diagnosis of NSCLC with unresectable, medically inoperable disease, or patients who refuse resection stage IIIA or stage IIIB disease (AJCC th edition)
Have histologically or cytologically confirmed stage IIIB (and not a candidate for definitive multimodality therapy) or stage IV NSCLC.
Stage IIIb/C or Stage IV before complete resection
Stage IIIb/IV NSCLC
Histologically documented, locally advanced or recurrent (stage IIIB who are not eligible for combined modality treatment) or metastatic (Stage IV) NSCLC
Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test
Participants with no prior systemic treatment for advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC
Subjects with histologically-or cytologically-documented NSCLC [squamous (SQ) or nonsquamous (NSQ)] who present with Stage IIIB/Stage IV disease (according to version  of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or with recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection or definitive chemoradiotherapy for locally advanced disease)
Phase: Treatment nave: Must not have received any prior systemic anticancer treatment consisting of chemotherapy, immunotherapy, or targeted therapy for unresected stage IIIB to IV melanoma.
Currently receiving or less than  days since ending systemic anticancer treatment for unresected stage IIIB to IV melanoma
Measurable Stage IIIA or IIIB disease
Histologically confirmed advanced (Stage IIIB/IV) NSCLC (all histologies including squamous and sarcomatoid)
Participant has received more than one line of therapy for stage IIIB or IV disease
Subject with stage IIIB to IVMc melanoma for whom surgery is not recommended
Documented evidence of NSCLC (Stage IIIB/ IV disease)
Documented evidence of NSCLC (stage IIIB/IV disease)
Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC
Patient has stage IIIB or IV diagnosis and must have received one or two prior regimens (including platinum- doublet) of cytotoxic chemotherapy for the treatment of locally advanced or metastatic NSCLC.
Stage IIIB (AJCC Stage IIIB - Any T,NM or TNM) or Metastatic (AJCC Stage IV- any T, any N, M), progressive, recurrent or refractory NSCLC. Patients may not be eligible for other curative intent treatment (e.g., surgical resection). For the purpose of eligibility for this trial, the above-cited disease states are defined as follows:
Subjects with histologically or cytologically-documented non-squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemoradiation therapy for locally advanced disease) and who will receive study therapy as second or third line of treatment for advanced disease
Pathologically confirmed diagnosis of Stage IIIB / IV adenocarcinoma of the lung.
Cytologic or histologically diagnosed NSCLC in stages IIIA (non-resectable) or IIIB or IV (TNM).
Newly diagnosed and confirmed Stage IIIB/IV NSCLC
Stage IIIB, IIIC, or IV erbB (HER) positive breast cancer
Pathologic diagnosis of breast cancer and current stage IIIB, IIIC, or IV
Stage IIIB or Stage IV NSCLC who are not candidates for multimodality treatment and have received at least  line of standard platinum-based therapy:
Subject has histologically confirmed locally advanced or unresectable Stage IIIB (not amenable to receive curative treatments such as chemo-radiation)/IV or metastatic NSCLC.
Has locally advanced or metastatic disease (Stage IIIb or Stage IV) with radiographically or clinically evaluable lesions.
Histologically confirmed and documented previously treated Stage IIIB/IV NSCLC, having failed  previous platinum chemo regimen for locally advanced or metastatic disease.
Histologically or cytologically confirmed diagnosis of NSCLC that is Stage IIIb, IV, or recurrent.
Histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery, or chemoradiation therapy, with or without adjuvant or neoadjuvant chemotherapy).
Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC)
Patients with histologically or cytologically documented, locally advanced (stage IIIB who are not amenable to combined modality treatment) or recurrent or metastatic (Stage IV) non-small cell lung cancer.
Prior systemic treatment for Stage IIIB or IV non-squamous NSCLC
Histologically or cytologically confirmed Stage IIIB or IV advanced or metastatic NSCLC with measurable neoplastic disease. Sputum cytology alone is not considered an acceptable method of diagnosis;
Pathologically confirmed of advanced and/or metastatic stage IIIb/IV non-small cell carcinoma of lung
Histologically or cytologically documented advanced NSCLC who have Stage IIIB/Stage IV disease, or recurrent disease following radiation therapy or surgical resection or advanced, unresectable (Stage III) or metastatic (Stage IV) melanoma;
No prior treatment for unresectable Stage IIIB or IV NSCLC
Histologically or cytologically confirmed diagnosis: Arm A and B- stage IV recurrent metastatic squamous NSCLC with Fibroblast growth factor receptor  (FGFR) gene amplification by central laboratory testing. Arm C- recurrent after local therapy or unresectable MPM with measurable lesions. For specific arms the following requirements: Arm A: Subjects who have received no prior therapy for Stage IIIB or Stage IV or recurrent metastatic disease. Note, to avoid any undue delay of initiating systemic chemotherapy for these subjects with newly diagnosed metastatic disease, it is allowed to initiate the first cycle of chemotherapy while eligibility for the study is still being determined, as long as the first dose of GSK is given no later than Cycle  Day  of chemotherapy. In addition, subjects with Stage IIIB or Stage IV disease and recurrence after previous NSCLC that has been treated with surgery and adjuvant chemotherapy or a radio- chemotherapy regimen with curative intent are eligible, provided  months has passed since this treatment ended. Arm B: Subjects who have documented tumor progression (based on radiological imaging) or intolerability after receiving at least one prior line of platinum containing combination chemotherapy for Stage IIIB or Stage IV or recurrent metastatic disease. Note: Prior treatment should not include docetaxel but may have included paclitaxel. Arm C: Subjects who have received no prior systemic therapy for MPM.
Locally advanced or metastatic non-small cell lung cancer (stage IIIB or IV by AJCC th)
Recurrent, satellite or in-transit locally advanced cutaneous or subcutaneous melanoma metastases (i.e., AJCC Stage IIIB, IIIC or Stage IV Ma with no active nodal metastases)
Histological or cytological proven advanced (unresectable) or metastatic NSCLC as defined as stage IIIB (positive supraclavicular lymph nodes) not amenable to definitive chemoradiotherapy or stage IV NSCLC
Histologically or cytologically confirmed incurable Stage IIIb/IV NSCLC tumor
Histologic diagnosis of melanoma with in transit metastasis stage IIIB, IIIC, or IV
Part A: Histologic or cytologic diagnosis of advanced Non Small Cell Lung Cancer (NSCLC), Stage IIIB with malignant pleural effusion or Stage IV, completed at least  prior systemic regimen, and eligible for erlotinib therapy.
NSCLC: --Histologic or cytologic diagnosis of advanced NSCLC, Stage IIIB with malignant pleural effusion or Stage IV
Histologically or cytologically confirmed diagnosis of Stage IIIB or IV NSCLC
Stage IV or stage IIIB cancer
PATIENT: Be diagnosed with an incurable and advanced-stage solid malignancy (stage IIIB, IIIC, or IV)
Histological or cytological confirmation of Stage IIIb or Stage IV (unresectable) NSCLC
Patient has stage IIIB (and is not a candidate for definitive multimodality therapy) or has stage IV NSCLC or relapsed locally advanced or metastatic NSCLC as follows:
Locally advanced (stage IIIA-IIIB) or metastatic (stage IV) NSCLC
Locally advanced or metastatic (stage IIIB, stage IV, or recurrent) NSCLC with measurable lesions per RECIST version ..